Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Sonoma Pharmaceuticals (O8Z) Stock Price & Analysis

1 Followers

O8Z Stock Chart & Stats

€2.69€0.00(0.00%)
At close: 5:30 PM GMT+1
€2.75€3€3.25€3.5Nov 14Jan 9Jan 11Mar 7Jun 26
Day’s Range
EUR 2.69 - EUR 2.96
52-Week Range
EUR 2.69 - EUR 2.96
Previous Close
EUR 2.69
Volume
N/A
Average Volume (3M)
0
Market Cap
EUR 4.92M
Enterprise Value
EUR 2.28M
Total Cash (Recent Filing)
EUR 4.61M
Total Debt (Recent Filing)
EUR 602.00K
Price to Earnings (P/E)
―
Beta
N/A
Next Earnings
Feb 16, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Revenue Growth And Narrowing Losses

TTM revenue growth and materially narrower losses indicate improving commercial traction and movement toward breakeven. If this progression continues, a larger revenue base can improve operating leverage and make the Microcyn portfolio more capable of supporting durable earnings.

Conservative Balance Sheet

Low leverage and a stronger equity base reduce balance-sheet stress and refinancing exposure, giving Sonoma more flexibility to sustain operations and fund measured growth. This financial cushion is a durable strength while the company works toward consistent profitability.

Microcyn Platform And Channel Reach

The Microcyn platform supports multiple topical and wound-care applications and reaches customers through direct, distribution, licensing, and branding channels. This diversified commercialization model can broaden geographic access and encourage recurring demand for consumable healthcare products.

Bears Say

Persistent Cash Burn

Negative operating and free cash flow show that Sonoma is not yet self-funding its operations and investment needs. Continued cash burn can reduce financial flexibility and make progress toward sustainable growth dependent on improving cash conversion or obtaining additional resources.

Profitability Remains Negative

Although losses have narrowed, negative net and operating margins show that the current revenue base still does not consistently cover the company’s cost structure. Until profitability becomes durable, growth may not translate into retained capital or dependable earnings power.

Ownership-Change Restrictions

The rights plan protects net operating loss carryforwards and other tax benefits, but it also imposes a meaningful ownership threshold for investors. That restriction can limit the ease of share accumulation and constrain potential ownership changes while adding structural complexity for shareholders.

Sonoma Pharmaceuticals News

O8Z FAQ

What was Sonoma Pharmaceuticals’s price range in the past 12 months?
Sonoma Pharmaceuticals lowest stock price was €2.69 and its highest was €2.96 in the past 12 months.
What is Sonoma Pharmaceuticals’s market cap?
Sonoma Pharmaceuticals’s market cap is €4.92M.
When is Sonoma Pharmaceuticals’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Sonoma Pharmaceuticals’s earnings last quarter?
Sonoma Pharmaceuticals released its earnings results on Nov 10, 2026. The company reported €0.085 earnings per share for the quarter.
Is Sonoma Pharmaceuticals overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Sonoma Pharmaceuticals pay dividends?
Sonoma Pharmaceuticals does not currently pay dividends.
What is Sonoma Pharmaceuticals’s EPS estimate?
Sonoma Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sonoma Pharmaceuticals have?
Sonoma Pharmaceuticals has 4,788,425 shares outstanding.
What happened to Sonoma Pharmaceuticals’s price movement after its last earnings report?
Sonoma Pharmaceuticals reported an EPS of €0.085 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Sonoma Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:O8Z
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology